Skip to content

Post Marketing Surveillance Study (PMS) to generate safety and efficacy data of Desvenlafaxine and Clonazepam tablets

Prescriber Based, Post Marketing Surveillance Study (PMS) to generate safety and efficacy data of Desvenlafaxine and Clonazepam tablets

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/026111
Enrollment
200
Registered
2020-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F339- Major depressive disorder, recurrent, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Akums Drugs and Pharmaceuticals Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex of age 18 to 60 years [both inclusive] 2. Willing to give written informed consent 3. All patients clinically manifesting with symptoms of major depressive disorder

Exclusion criteria

Exclusion criteria: 1) Patients known, or thought to be hypersensitivity to study drug 2) History of auto-immune disease 3) Concurrent use of corticosteroids 4) Any medication or indication that might point to an increased risk, associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion 5) Participation in other clinical trials the last three months and during study participation 6) Patients with history of epilepsy, or those at risk for seizures or taking seizure drugs 7) Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control 8) Patients with galactose or fructose intolerance 9) Patients with severe renal impairment, including those receiving dialysis. 10) Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities. 11) Patients with preexisting gallbladder disease 12) Active peptic ulcer disease

Design outcomes

Primary

MeasureTime frame
The primary objective of this PMS is to evaluate safety and tolerability of this FDC in treatment of major depressive disorder in the actual field conditions of use.Timepoint: 4 Weeks

Secondary

MeasureTime frame
The secondary objective of this PMS is to evaluate efficacy of this FDC in treatment of major depressive disorder in the actual field conditions of use.Timepoint: 4 Weeks

Countries

India

Contacts

Public ContactMamta Sharma

CRO PHARMATRENDZ PRIVATE LIMITED

drsai@pharmatrendz.com9861252518

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026